Skip to main content

Shares in Bio-Rad Slide 7.12 Percent on Declining Q2 Profit

NEW YORK, Aug. 5 (GenomeWeb News) - Shares in Bio-Rad slipped 7.12 percent, or $4.42, to $57.63 after the company posted a 9-percent decline in profit.

 

As GenomeWeb News reported, Bio-Rad said total receipts for the period ended June 30 increased 11.8 percent to $291.3 million $260.5 million during the same period. The growth was due to strong sales in the areas of diabetes monitoring, blood virus screening, quality controls, protein expression analysis, and amplification products. This latter category grew in part because of Bio-Rad's acquisition of MJ Research.

 

Research and development costs increased to $28.5 million from $25.5 million during the same quarter a year ago.

 

Bio-Rad's net income for the quarter fell 9.3 percent to $18.4 million, or $.71 per share, from $22.9 million, or $.79 per share, during last year's second quarter. The company attributed this decrease to its continuing investment in systems and infrastructure and increased interest expenses associated with the sale of bonds at the end of last year.

 

As of June 30, Bio-Rad had $252.1 million in cash and cash equivalents, $35.6 million in restricted cash, and $91.3 million in short-term investments.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.